BNP Paribas Financial Markets Has $70.21 Million Position in Illumina, Inc. $ILMN

Key Points

• BNP Paribas Financial Markets increased its holdings in Illumina, Inc. by 49.9% in Q1, owning approximately 0.56% of the company, valued at $70.2 million.
• Several large investors, including Beck Bode LLC and Quantitative Investment Management LLC, significantly raised their positions in Illumina during the same period, indicating a strong interest from institutional investors.
• Illumina reported Q2 earnings of $1.19 EPS, surpassing estimates of $1.02, while revenue declined 4.8% year-over-year to $1.06 billion.

BNP Paribas Financial Markets grew its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 49.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 884,896 shares of the life sciences company's stock after buying an additional 294,609 shares during the quarter. BNP Paribas Financial Markets owned 0.56% of Illumina worth $70,208,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of ILMN. Rakuten Securities Inc. raised its holdings in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after buying an additional 270 shares in the last quarter. Center for Financial Planning Inc. bought a new position in Illumina during the 1st quarter valued at about $33,000. Fourth Dimension Wealth LLC bought a new position in Illumina during the 4th quarter valued at about $40,000. PFS Partners LLC lifted its holdings in Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares during the last quarter. Finally, Golden State Wealth Management LLC lifted its holdings in Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ILMN shares. Citigroup downgraded shares of Illumina from a "hold" rating to a "strong sell" rating and cut their price target for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Royal Bank Of Canada set a $124.00 price target on Illumina in a report on Tuesday. Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target for the company. in a report on Tuesday, August 12th. Morgan Stanley raised their price target on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a report on Monday, August 4th. Finally, Robert W. Baird raised their price target on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Six investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $123.06.

Illumina Trading Up 0.6%

Shares of Illumina stock traded up $0.60 during trading on Thursday, reaching $96.67. 711,022 shares of the company were exchanged, compared to its average volume of 2,284,960. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The business has a 50-day moving average price of $99.47 and a 200-day moving average price of $88.58. The firm has a market capitalization of $14.86 billion, a price-to-earnings ratio of 12.23, a P/E/G ratio of 2.25 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.